Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

Chemoimmunotherapy (CIT) is still standard treatment for patients with chronic lymphocytic leukemia (CLL), particularly when favourable risk factors are present, although this treatment is not suitable for all patients due to the severe side effects. This study shows that targeted therapy combinations can improve PFS.